KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Inventory (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Inventory for 8 consecutive years, with $10.3 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 26.05% to $10.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.3 million through Dec 2025, up 26.05% year-over-year, with the annual reading at $10.3 million for FY2025, 26.05% up from the prior year.
  • Inventory hit $10.3 million in Q4 2025 for Castle Biosciences, up from $8.6 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $10.3 million in Q4 2025 to a low of $2.0 million in Q4 2021.
  • Historically, Inventory has averaged $5.6 million across 5 years, with a median of $5.9 million in 2023.
  • Biggest five-year swings in Inventory: skyrocketed 99.55% in 2023 and later decreased 10.41% in 2025.
  • Year by year, Inventory stood at $2.0 million in 2021, then surged by 96.93% to $4.0 million in 2022, then surged by 99.55% to $7.9 million in 2023, then grew by 2.43% to $8.1 million in 2024, then rose by 26.05% to $10.3 million in 2025.
  • Business Quant data shows Inventory for CSTL at $10.3 million in Q4 2025, $8.6 million in Q3 2025, and $8.4 million in Q2 2025.